Form 4: Apogee Therapeutics' Chief Medical Officer Sells Shares Under 10b5-1 Trading Plan

Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, sold common stock in multiple transactions on April 2, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Carl Dambkowski, the Chief Medical Officer of Apogee Therapeutics, Inc. (APGE), reported the sale of common stock on April 2, 2025.
• The sales were executed under a Rule 10b5-1 trading plan adopted on August 21, 2024.
• A total of 3,860 shares were sold in multiple transactions at varying prices.
• The weighted average sale prices ranged from $35.56 to $37.59 per share.
• Following the reported transactions, Dambkowski beneficially owns 247,173 shares of Apogee Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating insider trading activity under a pre-arranged plan. It's neutral in sentiment as it simply reports transactions.

Industry Context

Sales by company insiders are a common occurrence and are often scrutinized by investors. The use of a 10b5-1 trading plan allows insiders to sell shares over a predetermined period, mitigating concerns about trading on non-public information.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.

Key Dates

Keywords

Apogee Therapeutics, Carl Dambkowski, Form 4, SEC, Stock Sale, Rule 10b5-1, Chief Medical Officer, APGE